2024-511181-36-00撤回3 期
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa
Beacon Therapeutics (USA) Inc.1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2024年9月17日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint in Europe is the change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry, at Month 12
研究概览
简要总结
Primary objective in Europe is to evaluate the efficacy of two doses of AGTC-501 after a single subretinal administration compared to an untreated control as assessed by macular integrity assessment (MAIA) microperimetry at Month 12
入排标准
- 年龄范围
- 0 years 至 64 years（18-64 Years, 0-17 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent or assent (per local regulation), prior to the conduct of any study-related procedure. Participants who provide assent must have a parent, guardian, or legal representative provide written informed consent.
- •Be able to perform all tests of visual and retinal function and structure in both eyes based on the participant’s reliability, and fixation, in the study eye per the Investigator’s discretion.
- •Have detectable baseline mean macular sensitivity measured by MAIA microperimetry, between 1-12 dB in the study eye, as determined by the Investigator and confirmed by the Central Reading Center (CRC), with fixation loss ≤20% at each screening visit.
- •Have a detectable sub-foveal ellipsoid zone (EZ) line as assessed by SD-OCT in the study eye and confirmed by the CRC.
- •If both eyes meet all entry criteria, the study eye is the worse-seeing eye as measured by ETDRS BCVA. If both eyes are eligible and have the same BCVA, the choice of study eye will be at the discretion of the Investigator and/or Surgeon.
- •Be between 12 and 50 years of age (inclusive) at the time of informed consent and assent (as applicable).
- •Be male (XY chromosome) and have at least one documented pathogenic or likely pathogenic variant in the RPGR gene within exons 1-14 and/or ORF15 from a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratory.
- •Have a clinical diagnosis of XLRP.
- •Be in good general health to withstand subretinal surgery and perioperative medications based on a complete physical examination and hematology and clinical chemistry evaluations performed at screening.
- •Be able and willing, as assessed by the Investigator, to follow study instructions, complete study assessments, comply with the protocol, and attend study visits for the duration of the study.
- •If the participant has a parent or caregiver, the parent or caregiver must be able to follow study instructions, comply with the protocol, and attend study visits with the participant, as required.
- •Have a BCVA ≤ 78 letters (approximately Snellen, 20/32) and ≥ 34 letters (approximately Snellen, 20/200) based on an ETDRS chart at each screening visit. ETDRS letter score is the main VA inclusion criterion for participants. Participants unable to read the ETDRS letters may utilize a tumbling “E” chart for BCVA assessments.
- •Have a LLVA ≤64 letters (approximately Snellen 20/50) in the study eye based on an ETDRS chart at each screening visit. Participants unable to read the ETDRS letters may utilize a tumbling “E” chart for LLVA assessments.
排除标准
- •Have other known disease-causing mutations documented in the participant’s medical history or identified through a retinal dystrophy gene panel that, in the opinion of the Investigator, would interfere with the potential therapeutic effect of the study agent or the quality of the assessments
- •Are currently participating or recently participated in any other research protocol involving investigational agents or therapies that would make the participant unsuitable for the study. Recent participation is defined as participation within 90 days of initial screening for this study OR within 10 half-lives of the investigational drug, whichever is longer.
- •Have previously received any AAV gene therapy product, stem cell therapy, cell-based therapy, or similar biologics.
- •Have pre-existing eye conditions that would preclude the planned surgery, interfere with the interpretation of study endpoints, or increase the risk of surgical complications (e.g., corneal opacities, diabetic retinopathy, retinal vasculitis, glaucoma, active cystoid macular edema [CME]).
- •Have significant media opacity impacting evaluation of the retina or vitreous. This includes cataracts considered to be a major contributor to reducing visual acuity and/or if the participant is likely to require cataract extraction within 3 months of study treatment administration.
- •Had intraocular surgery within 90 days of study treatment administration (Day 1).
- •Have any active ocular/intraocular infection or inflammation (e.g., severe blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis, idiopathic or autoimmune-associated uveitis, or herpetic lesions).
- •Have a history of corticosteroid-induced raised intraocular pressure (IOP) of >25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy.
- •Have any artificial retinal implant or prosthesis.
- •Have absence of clear ocular media and/or inadequate pupil dilation to facilitate good quality SD-OCT images.
- •Have any history of rhegmatogenous retinal detachment.
- •For participants with herpes simplex virus (HSV): a. Have history of oral or genital herpes and are unable and/or unwilling to utilize prophylactic antiviral medication. b. Have a history of ocular herpes. c. Have active oral or genital herpes or are currently receiving treatment for HSV infection.
- •Have myopia (spherical equivalent) exceeding −10 diopters (or axial length of >30 mm if PI deems it appropriate to measure) or presence of pathologic myopia in the study eye.
- •Have passed the Low Contrast Ora-VNC mobility course ≤0.35 lux light level in either eye or binocularly at any screening visit.
- •Have complicating systemic diseases (e.g., medical conditions causing immunosuppression, autoimmunity, active systemic infection) that would preclude the gene transfer or ocular surgery if not adequately managed or treated.
- •Have known sensitivity or allergy to systemic corticosteroids or other immunosuppressive medications.
- •Have used anti-coagulant agents that may alter coagulation (e.g., warfarin, heparin, apixaban, or high dose docosahexaenoic acid [DHA; fish oil]) within 7 days prior to study treatment administration (ibuprofen, aspirin, or similar are acceptable).
- •Have received any vaccination/immunization within 28 days prior to screening and/or during screening, except for the influenza vaccine, which is only exclusionary if they have received the influenza vaccine within 28 days prior to randomization.
- •Have used systemic corticosteroids or other immunosuppressive medications within 3 months prior to screening and/or intend to use during screening. Corticosteroids used on an as-needed basis administered by insufflation, inhalation, or local administration to the skin and mucosa, such as Symbicort (budesonide/formoterol), Flonase (fluticasone propionate), and skin creams and ointments containing corticosteroids shall not be exclusionary.
- •If sexually active or planning to become sexually active, are unwilling to use barrier contraception for 3 months following treatment administration.
- •Have any other condition or reason that, in the opinion of the Investigator, would prevent a participant from completing study assessments during the study.
结局指标
主要结局
The primary efficacy endpoint in Europe is the change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry, at Month 12
The primary efficacy endpoint in Europe is the change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry, at Month 12
次要结局
- Change from baseline in mobility test score at Month 12 as measured by the Ora-VNC mobility course
- Change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry at Month 18
- Response at Month 12, as measured by MAIA microperimetry, where response is defined as a ≥7 decibel (dB) visual sensitivity improvement from baseline in at least 5 loci
- Change from baseline in mobility test score at Month 12 as measured by the MObility Standardized Test-Virtual Reality (MOST-VR) mobility course
- Change from baseline in full-field stimulus threshold (FST) at Month 12
- Change from baseline in mean sensitivity across the central 4 loci, as measured by MAIA microperimetry, at Month 12
- Proportion of participants with a ≥15 letter increase from baseline in LLVA at Month 18 and 24
- Change in low-luminance deficit (LLD), defined as the difference between BCVA and LLVA Month 12
- Change from baseline in BCVA over time as assessed by an Early Treatment of Diabetic Retinopathy (ETDRS) or Tumbling E chart at Month 12
- Response by Ora-VNC where response is defined as a mobility test score increase of 2 or more luminance levels at Month 12
- Change from baseline in mean sensitivity across the whole grid, as measured by MAIA microperimetry at Month 24
- Response at Month 18 and 24, as measured by MAIA microperimetry, where response is defined as a ≥7 decibel (dB) visual sensitivity improvement from baseline in at least 5 loci
- Change from baseline in full-field stimulus threshold (FST) at Month 24
- Change from baseline in mean sensitivity across the central 4 loci, as measured by MAIA microperimetry, at Month 18 and Month 24
- Proportion of participants with a ≥10 letter increase from baseline in LLVA at Month 12, 18 and 24
- Change in low-luminance deficit (LLD), defined as the difference between BCVA and LLVA Month 18 and 24
- Change from baseline in BCVA over time as assessed by an Early Treatment of Diabetic Retinopathy (ETDRS) or Tumbling E chart at Month 18 and 24
- Change from baseline in mobility test score at Month 18 and 24 as measured by the Ora-VNC mobility course
- Response by Ora-VNC where response is defined as a mobility test score increase of 2 or more luminance levels at Month 18 and 24
- Efficacy: Change from baseline in spectral-domain optical coherence tomography (SD-OCT) EZ line over time
- Efficacy: Response over time, as measured by MAIA microperimetry, defined as ≥7 dB visual sensitivity improvement from baseline in 5 prespecified loci
- Efficacy: Change from baseline in domain scores from the Michigan Retinal Degeneration Questionnaire (MRDQ), over time
- Safety: The primary safety endpoint is the number and proportion of participants with ocular/non-ocular AEs
研究者
Tricia Racanelli
Scientific
Beacon Therapeutics (USA) Inc.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
已完成
2 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)2024-512095-35-00Novartis Pharma AG49
已完成
1 期
QTc Assessment in a Single-Dose Study of Hydronidone CapsulesHepatic FibrosisNCT07263152Beijing Continent Pharmaceutical Co, Ltd.48
招募中
2 期
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye DiseaseThyroid Eye Disease2024-514110-12-00Amgen Inc.16
招募中
2 期
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk of relapse2023-505223-31-00European Organisation For Research And Treatment Of Cancer347